We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

61 hedge funds and large institutions have $34.6M invested in Summit Therapeutics in 2022 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 18 increasing their positions, 7 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

819% more capital invested

Capital invested by funds: $3.76M → $34.6M (+$30.8M)

178% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 9

157% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 7

36% more funds holding

Funds holding: 45 → 61 (+16)

21% more call options, than puts

Call options by funds: $5.59M | Put options by funds: $4.63M

2.44% more ownership

Funds ownership: 1.59% → 4.03% (+2.4%)

Holders
61
Holders Change
+16
Holders Change %
+35.56%
% of All Funds
0.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
18
Reduced
7
Closed
9
Calls
$5.59M
Puts
$4.63M
Net Calls
+$952K
Net Calls Change
+$858K

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$3.64M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.21M
3
Marshall Wace
Marshall Wace
United Kingdom
+$877K
4
SPIA
Steward Partners Investment Advisory
New York
+$555K
5
AIC
AWM Investment Company
New York
+$546K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$514K
2
Morgan Stanley
Morgan Stanley
New York
-$241K
3
UBS Group
UBS Group
Switzerland
-$85.2K
4
Group One Trading
Group One Trading
Illinois
-$39.5K
5
Wells Fargo
Wells Fargo
California
-$28K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$8.5M +$3.64M +2,000,000 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$6.14M +$1.21M +667,636 +86%
Marshall Wace
3
Marshall Wace
United Kingdom
$2.65M +$877K +482,206 +343%
BlackRock
4
BlackRock
New York
$2.27M +$207K +113,574 +27%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$2M +$268K +147,381 +45%
SPIA
6
Steward Partners Investment Advisory
New York
$1.3M +$555K +305,000 New
AIC
7
AWM Investment Company
New York
$1.27M +$546K +300,000 New
Two Sigma Investments
8
Two Sigma Investments
New York
$1.22M +$521K +286,200 New
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$1.19M +$361K +198,717 +243%
BFM
10
Boothbay Fund Management
New York
$940K +$402K +221,205 New
Morgan Stanley
11
Morgan Stanley
New York
$930K -$241K -132,400 -38%
AGM
12
Alpine Global Management
New York
$862K +$369K +202,928 New
DekaBank Deutsche Girozentrale
13
DekaBank Deutsche Girozentrale
Germany
$531K +$182K +100,000 New
BCM
14
Bridgeway Capital Management
Texas
$379K – – –
State Street
15
State Street
Massachusetts
$374K +$160K +87,900 New
KI
16
Kapitalo Investimentos
Brazil
$243K +$104K +57,200 New
Jane Street
17
Jane Street
New York
$241K +$66.2K +36,396 +180%
Goldman Sachs
18
Goldman Sachs
New York
$236K -$9.51K -5,229 -9%
Citigroup
19
Citigroup
New York
$235K +$96K +52,801 +2,071%
6CM
20
683 Capital Management
New York
$216K +$92.5K +50,838 New
Northern Trust
21
Northern Trust
Illinois
$215K +$50.2K +27,591 +120%
Citadel Advisors
22
Citadel Advisors
Florida
$206K +$88K +48,378 New
Osaic Holdings
23
Osaic Holdings
Arizona
$197K +$10.6K +5,800 +14%
Mercer Global Advisors
24
Mercer Global Advisors
Colorado
$183K +$1.46K +800 +2%
VEA
25
Virtus ETF Advisers
New York
$182K +$77.9K +42,835 New
1
2 3

SMMT Hedge Fund Activity: Q4 2022 in Review

61 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q4 2022, worth a combined $34.6M — up 819% from $3.76M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new SMMT positions and 9 closed out — a net gain of 16 holders — while 18 added to existing stakes and 7 trimmed.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $3.64M. The largest seller was Millennium Management, exiting entirely with an estimated $514K sold.

  • 61 institutional investors held Summit Therapeutics (SMMT) as of Q4 2022, up from 45 in Q3 2022.
  • Funds reported $34.6M of Summit Therapeutics stock for Q4 2022, up 819% quarter-over-quarter.
  • 25 funds opened new Summit Therapeutics positions in Q4 2022 and 9 closed out, a net change of +16 holders.
  • The largest Summit Therapeutics buyer in Q4 2022 was Baker Bros. Advisors, an estimated $3.64M added.
  • The largest Summit Therapeutics seller in Q4 2022 was Millennium Management, an estimated $514K sold.

Based on aggregated 13F filings for Q4 2022.